Oops didn't get all the first post last time. Try try again
This might help.
"As a young man, before earning graduate degrees in medicine and pharmacology, Dr. Menon was the chief veterinarian for a Jamaican parish, which is comparable to an American state. On one occasion, he was called to do a postmortem analysis following the mysterious death of an expensive prize bull. The investigation revealed that the animal had been treated with an agent designed to kill external parasites, a common problem in tropical countries.
During the postmortem analysis, Dr. Menon discovered that the tick-and-mite-killing product acted as a cytotoxic agent, causing organ failure. More importantly, however, he also observed that the bull had suffered from subcutaneous tumors, but many had been eliminated by the product.
The event marked the beginning of his quest to develop anti-cancer compounds that combine low toxicity with high efficacy. This theme has marked much of his career, and has already led to the creation of breakthrough cancer drugs. It is now reaching its culmination in Cellceutix’s leading compound, called Kevetrin"
http://www.hotstockmarket.com/t/259020/ctix-c...orporation
Apparently there was still some tweaking needed to the molecule in order to get it to work in humans and not be toxic. This early poster here on this board must have had some insight into this.
BigKahuna Thursday, 01/22/09 05:07:34 PM
Re: BigKahuna post# 39
Post # of 85123
Cellceutix needs a delivery vehicle for its Kevetrin. TherCour technology to the rescue? "
Apparently this is where Aruda comes into the picture through his company Agrenetics.
"Company Description
Agrenetics is a research and business development company which has developed a new proprietary method for the combinatorial synthesis of herbicides and small molecule drugs. The Company is pursuing multiple applications and collaborations with this technology and seeking potential marketing partners for other "spin-out" technologies developed in-house or with collaborators. Agrenetics is also investigating a variety of natural product extracts for biological and industrial utility."
http://www.massachusettslifescience.com/indus...anyid=6066
Apparently the patent issue arose from the fact that Menon initially considered Aruda's contribution as some sort of "contract labor" rather than being a co-inventor. (contract labor might be a poor choice of words and I am sure someone will take me to task over its use).
Aruda disagreed and pressed the issue. Menon agreed to grant Aruda 16 million of his shares in Cellceutix and royalties on future Kevetrin sales (2% I think)to clear the patent (which had been sold to Cellceutix). Upon the personal agreement the now cleared patent was retained by Cellceutix.
This might help.
"As a young man, before earning graduate degrees in medicine and pharmacology, Dr. Menon was the chief veterinarian for a Jamaican parish, which is comparable to an American state. On one occasion, he was called to do a postmortem analysis following the mysterious death of an expensive prize bull. The investigation revealed that the animal had been treated with an agent designed to kill external parasites, a common problem in tropical countries.
During the postmortem analysis, Dr. Menon discovered that the tick-and-mite-killing product acted as a cytotoxic agent, causing organ failure. More importantly, however, he also observed that the bull had suffered from subcutaneous tumors, but many had been eliminated by the product.
The event marked the beginning of his quest to develop anti-cancer compounds that combine low toxicity with high efficacy. This theme has marked much of his career, and has already led to the creation of breakthrough cancer drugs. It is now reaching its culmination in Cellceutix’s leading compound, called Kevetrin"
http://www.hotstockmarket.com/t/259020/ctix-c...orporation
Apparently there was still some tweaking needed to the molecule in order to get it to work in humans and not be toxic. This early poster here on this board must have had some insight into this.
BigKahuna Thursday, 01/22/09 05:07:34 PM
Re: BigKahuna post# 39
Post # of 85123
Cellceutix needs a delivery vehicle for its Kevetrin. TherCour technology to the rescue? "
Apparently this is where Aruda comes into the picture through his company Agrenetics.
"Company Description
Agrenetics is a research and business development company which has developed a new proprietary method for the combinatorial synthesis of herbicides and small molecule drugs. The Company is pursuing multiple applications and collaborations with this technology and seeking potential marketing partners for other "spin-out" technologies developed in-house or with collaborators. Agrenetics is also investigating a variety of natural product extracts for biological and industrial utility."
http://www.massachusettslifescience.com/indus...anyid=6066
Apparently the patent issue arose from the fact that Menon initially considered Aruda's contribution as some sort of "contract labor" rather than being a co-inventor. (contract labor might be a poor choice of words and I am sure someone will take me to task over its use).
Aruda disagreed and pressed the issue. Menon agreed to grant Aruda 16 million of his shares in Cellceutix and royalties on future Kevetrin sales (2% I think)to clear the patent (which had been sold to Cellceutix). Upon the personal agreement the now cleared patent was retained by Cellceutix.
